Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
DMAC Stock Chart & Stats
$5.99
-$0.24(-4.23%)
At close: 4:00 PM EST
$5.99
-$0.24(-4.23%)
Day’s Range― - ―
52-Week Range$3.28 - $10.42
Previous CloseN/A
Volume70.76K
Average Volume (3M)222.76K
Market Cap
$322.76M
Enterprise Value$307.35M
Total Cash (Recent Filing)$59.89M
Total Debt (Recent Filing)$240.00K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding53,882,507
10 Day Avg. Volume231,236
30 Day Avg. Volume222,757
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.60K
Enterprise Value/Ebitda-9.06
Forecast
1Y Price Target
$17.00Price Target Upside183.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Placental Safety And Maternal‑fetal BenefitDM199 does not cross the placenta and demonstrates strong vasodilation with early signs of improved placental perfusion, indicating potential to extend time to delivery and lower maternal‑fetal complications.
Rapid Blood Pressure EffectStatistically significant and clinically meaningful blood pressure reductions with rapid onset at higher doses suggest DM199 could provide immediate control of severe hypertension in preeclampsia.
Regulatory EngagementA pre‑IND meeting with the FDA to discuss Phase 2 plans for DM199 in preeclampsia reduces regulatory uncertainty and supports smoother trial initiation in the US.
Bears Say
Development Timeline And Cost PressureEnrollment shortfalls could lengthen development timelines and increase trial costs, raising potential financing needs and pressure on investor expectations.
Enrollment SlowdownLower than expected ongoing enrollment driven by changes in stroke referral patterns may slow trial progress and delay clinical milestones.
Referral Pattern DependenceDependence on transfers to large stroke center research sites creates vulnerability when referral patterns shift, reducing the pool of eligible patients for stroke studies.
Diamedica Therapeutics News
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $3.28 and its highest was $10.42 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Diamedica Therapeutics Inc’s market cap is $322.76M.
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is May 19, 2026 which is in 36 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on Mar 30, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.01.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 53,882,507 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went up 1.958%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diamedica Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (183.81% Upside)
$17.00 (183.81% Upside)
Blogger Sentiment
Neutral
DMAC Sentiment 50%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.6%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
70.65%
12-Months-Change
Fundamentals
Return on Equity
-77.62%
Trailing 12-Months
Asset Growth
32.42%
Trailing 12-Months
Company Description
Diamedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DMAC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress and multiple near-term catalysts: positive preeclampsia interim data (BP and uteroplacental perfusion improvements), Health Canada clearance for a global Phase II early-onset study, encouraging momentum and DSMB clearance in the ReMEDy2 stroke trial, and a strengthened cash position with runway into end-2027. Offsetting these positives are higher cash burn and operating expenses, a regulatory/preclinical complication with the rabbit reproductive tox request that could delay U.S. plans, earlier site staffing delays (now being addressed), and the risk that the stroke program may require a substantially larger sample size (up to 728) if interim results warrant re‑estimation. On balance, the company demonstrated robust scientific and operational progress with manageable but real regulatory, timing and cost risks.View all DMAC earnings summariesDMAC Stock 12 Month Forecast
Average Price Target
$17.00
▲(183.81% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Rocket Pharmaceuticals
―
Benitec Biopharma
―
Annexon Biosciences
―
Ownership Overview
45.56% Insiders
2.88% Mutual Funds
― Other Institutional Investors
48.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---